İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2024 · article

Multicenter evaluation of ceftazidime-avibactam use in carbapenem-resistant Klebsiella pneumoniae bloodstream infections in OXA-48 endemic regions

ISSN2045-2322
YÖKSİS OpenAlex Açık erişim · gold
Yıl2024
Atıf15OpenAlex
Yüzdelik%87,0
FWCI1,891,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q1

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıSCIENTIFIC REPORTS
  • Katalog eşleşmesi (ISSN)Scientific Reports
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

Data in the literature on the use of ceftazidime-avibactam (CAZ-AVI) in carbapenem-resistant Klebsiella pneumoniae bloodstream infections (CRKP-BSIs) are limited especially in OXA-48 (Oxacillinase-48) predominant regions. Our study aimed to evaluate the effect of CAZ-AVI use on outcomes in CRKP-BSIs in Turkey, where OXA-48 is endemic. A multicenter retrospective observational study was conducted between January 2017 and September 2021. The effects of clinical and treatment characteristics on 30-day mortality and relapse in CRKP-BSIs were analyzed. Predictors of outcomes were detected using a Cox regression model. The study enrolled 106 adults with CAZ-AVI-sensitive CRKP-BSIs who received CAZ-AVI for at least 72 h. Patients who received CAZ-AVI as initial therapy had lower mortality rates when compared to those who switched from last resort regimens [14.3% (n = 3/21) vs. 37.7% (n = 32/85), p = 0.04]. In multivariate analysis, older age and severe neutropenia were detected to be associated with higher mortality, significantly. Initiation of CAZ-AVI on the day of blood culture was obtained, was found to be significantly associated with lower mortality (HR: 0.25, CI: 0.07-0.84, p = 0.025). CAZ-AVI monotherapy is an important treatment option for CRKP-BSIs in OXA-48 endemic areas. Early initiation of CAZ-AVI should be preferred rather than switching from a last-resort regimen as it profoundly improves the survival rates.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

15atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 4 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2026 Infection-related mortality after hematopoietic stem cell transplantation in a high antimicrobial resistance settingAtıf 0 · OpenAlex
  2. 2026 Combating Carbapenem-Resistant Enterobacterales: Comparative In Vitro Efficacy of Aztreonam–Avibactam and Ceftazidime–Avibactam and Distribution of Carbapenemase GenesAtıf 0 · OpenAlex
  3. 2026 Multicenter Point-Prevalence Study of Carbapenem-Resistant Klebsiella spp. in Türkiye: Epidemiology, Antimicrobial Resistance, and Infection Control PracticesAtıf 0 · OpenAlex
  4. 2026 Rising antimicrobial resistance in urinary tract infections in Türkiye: an urgent need for update on regional treatment strategies and for enhanced antimicrobial stewardship effortsAtıf 0 · OpenAlex

Yazarlar

20
  1. ALİ MERT 1
  2. OKAN DERİN 2
  3. EMİN HALİS AKALIN BURSA ULUDAĞ ÜNİVERSİTESİ 3
  4. RIDVAN DUMLU 4
  5. SİBEL GÜNDEŞ 5
  6. REHİLE ZENGİN 6
  7. AYŞE SESİN KOCAGÖZ 7
  8. YASEMİN GÜNDOĞDU 8
  9. İFTİHAR KÖKSAL 9
  10. DEMET YALÇIN 10
  11. CEMAL ÜSTÜN 11
  12. MAHİR KAPMAZ 12
  13. LEVENT GÖRENEK 13
  14. KADRİYE KARAHANGİL 14
  15. FÜSUN CAN 15
  16. MEHMET ÖNDER ERGÖNÜL KOÇ ÜNİVERSİTESİ 16
  17. GÜLAY İMADOĞLU YETKİN İSTANBUL ATLAS ÜNİVERSİTESİ 17
  18. İFTAHAR KÖKSAL ACIBADEM MEHMET ALİ AYDINLAR ÜNİVERSİTESİ 18
  19. RIZA AYTAÇ ÇETİNKAYA İSTANBUL NİŞANTAŞI ÜNİVERSİTESİ 19
  20. SERAP GENÇER ACIBADEM MEHMET ALİ AYDINLAR ÜNİVERSİTESİ 20